Intra-Cellular Therapies Inc at Goldman Sachs Healthcare Conference Transcript
All right. Well, we're getting started. Great to see you. Thanks, everyone, for joining us today, and thanks for the team from Intra-Cellular for joining us as well. Maybe just we could start with a brief overview. If you could -- brief overview on where the company stands today and what you see as key value drivers over the next 12 to 24 months?
Right, so thanks. It's great to be here. Although it's nice and warm in here, so that's really terrific as opposed to out there where it's pretty cold. So let me just give you an overview on the company. We started the company in 2002. And what's great today, first of all, is our first product, CAPLYTA, which first got approval in 2019 for the treatment of schizophrenia in adults. Fast forward to December 2021 and received a label expansion for the treatment of bipolar depression.
And really, in the past year, since that launch for bipolar depression, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
